Abstract:Abstract Weight gain during chemotherapy for breast cancer is a well-documented adverse side effect. The prevalence of metabolic syndrome (MetS), including glucose intolerance, hypertension and dyslipidaemia in breast cancer patients are further exacerbated by menopause. This impact on mortality is relevant as many women with early-stage breast cancer may be treated however experience a greater risk of developing chronic disease, higher rates of cancer recurrence, and post-diagnosis death. Intentional weight loss of 5-10% body weight and muscle mass preservation has found to improve metabolic markers. We evaluated how multidisciplinary weight management involving endocrinology, dietitian and exercise physiology care, in a real-life Healthy Weight Clinic (HWC) could affect body weight and mass composition outcomes in breast cancer women receiving adjuvant chemotherapy compared to a cohort of non-cancer women who have been matched by age, ethnicity, smoking and menopausal status. Body weight (kg), BMI (kg/m 2), skeletal muscle mass (SMM %), fat mass (FM %) and waist circumference (cm) were collected at three time points: baseline 0-months at the first HWC appointment, 3-months after baseline, and 6-months after baseline. A total of 32 women were included in the study, 11 in the breast cancer cohort and 21 in the control cohort. There were significant changes in weight, BMI, SMM, FM and waist circumference for the breast cancer cohort at all time intervals. By 6-months, the breast cancer women had a mean weight change of -6.99kg (SD=3.87, p=. 003, n=11) and change in BMI by -2.72kg/m 2 (SD=1.62, p=. 004, n=11). There was a change in SMM of 1.21% (SD=0.73, p=. 005, n=11), a change in FM of -2.76% (SD=1.33, p=. 002, n=11) and a change in waist circumference of -8.13cm (SD=4.21, p=. 031, n=3). The control cohort had similar trend changes in weight, BMI and waist circumference, however there was no statistically significant change in SMM or FM over time. By 6-months in the breast cancer cohort, there was a larger reduction in body weight in women who did not have MetS (-8.72kg, SD=2.41, n=6) in comparison to women with MetS (-2.65kg, SD=3.75kg, n=3) (p=. 045). For the control cohort, anthropometric outcomes were not impacted by MetS status (p>. 05). Although these findings are in a small sample size, it appears that multidisciplinary weight management has a positive role in early-stage breast cancer survival through improving body weight and mass composition outcomes. Targeting pre-existing MetS status through lifestyle changes is also an important consideration, beyond a specific weight focus. Presentation: No date and time listed

Chemotherapy-induced weight gain in early-stage breast cancer: a prospective matched cohort study reveals associations with inflammation and gut dysbiosis

Effect of Chemotherapy on the Gut Microbiome of Breast Cancer Patients During the First Year of Treatment

The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer

Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy

Weight Change in Post-Menopausal Women with Breast Cancer during Chemotherapy-Perspectives on Nutrition, Activity and Bone Metabolism: An Interim Analysis of a 5-Year Prospective Cohort

Microbial Alterations and Risk Factors of Breast Cancer: Connections and Mechanistic Insights

Preliminary Analysis of Gut Microbiome and Gastrointestinal Symptom Burden in Breast Cancer Patients Receiving Chemotherapy Compared to Healthy Controls

Is There an Interplay between Environmental Factors, Microbiota Imbalance, and Cancer Chemotherapy-Associated Intestinal Mucositis?

Body weight changes after adjuvant chemotherapy of patients with breast cancer: results of a Mexican cohort study

Change Of Body Weight And Macrophage Inhibitory Cytokine-1 During Chemotherapy In Advanced Gastric Cancer: What Is Their Clinical Significance?

The Impact of Multidisciplinary Weight Management on Body Weight and Body Mass Composition in Women with Breast Cancer Post-Adjuvant Chemotherapy: A Retrospective Chart Review

Manipulations of the gut microbiome alter chemotherapy-induced inflammation and behavioral side effects in female mice

Systemic inflammation and changes in physical well-being in patients with breast cancer: a longitudinal study in community oncology settings

Body weight change in women receiving adjuvant chemotherapy for breast cancer: a French prospective study

Gut Microbiota-Driven Metabolic Alterations Reveal the Distinct Pathogenicity of Chemotherapy-Induced Cachexia in Gastric Cancer

ODP006 Multidisciplinary Weight Management Improves Body Weight And Body Mass Composition In Breast Cancer Women Undergoing Adjuvant Chemotherapy

Gut microbiota alterations induced by intensive chemotherapy in acute myeloid leukaemia patients are associated with gut barrier dysfunction and body weight loss

Insulin resistance and weight gain in women treated for early stage breast cancer

Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment

Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis

Chemotherapy-induced gut microbiome disruption, inflammation, and cognitive decline in female patients with breast cancer